On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...

The FDA has approved Karuna/Bristol Myers Squibb’s KarXT (Cobenfy) — an oral dual M1/M4 muscarinic acetylcholine receptor (mAChR) agonist — for schizophrenia. The fixed-dose combination of ...

The first new kind of treatment for schizophrenia patients in decades is arriving. The U.S. Food and Drug Administration ...

The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.

Muscarinic receptors are involved with neurotransmission via acetylcholine and glutamate, and are hypothesised to be dysfunctional in schizophrenia. Most drugs developed to treat schizophrenia to ...

Cobenfy was approved to reduce the psychotic symptoms associated with schizophrenia. It is a new type of medicine that works ...

The U.S. Food and Drug Administration has granted approval to Cobenfy, the first new schizophrenia drug in decades.

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Serotonin (5-hydroxytryptamine [5-HT]) receptor subtypes, such as the 5-HT 1A receptor, are considered to mediate the ability of antipsychotic drugs to enhance cognition. On the other hand ...

Bristol-Myers Squibb (BMY) stock rises as FDA approves Cobenfy as a ovel treatment for adults with the psychiatric disorder ...

The FDA has approved Cobenfy, the first new schizophrenia treatment in 30 years, offering a novel approach with fewer side ...